|Bid||105.66 x 800|
|Ask||105.67 x 800|
|Day's Range||104.31 - 105.92|
|52 Week Range||73.69 - 105.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 23, 2018|
|Forward Dividend & Yield||2.25 (2.21%)|
|1y Target Est||97.13|
Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 16) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Eli Lilly And ...
Eli Lilly and Co.'s ( LLY) stock has jumped by more than 16% since the middle of July and by nearly 24% in 2018. The stock is poised to plunge 15% in the coming weeks, based on technical analysis. Eli Lilly's stock broke out following better-than-expected quarterly results and guidance, rising above a long-term technical resistance level around $88.50.
Bausch Health Companies’ (BHC) wholly-owned subsidiary Ortho Dermatologics generated revenue of $142.0 million in the second quarter compared to $162 million in the second quarter of 2017, reflecting a ~12% YoY (year-over-year) fall.
Karuna Pharmaceuticals Inc., which is developing treatments for schizophrenia and other neurological conditions, has appointed Chairman Steven Paul as chief executive.
Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).
Elanco will place the net proceeds of the Offering into escrow, to be released upon either the completion of its previously announced, anticipated initial public offering (IPO) or a special mandatory redemption, which would occur if the IPO does not take place, or Lilly otherwise determines that the IPO will not take place, by June 30, 2019. Elanco intends to pay the net proceeds of the Offering as part of the consideration to Lilly.
Nektar Therapeutics (NKTR) generated revenue of $1.09 billion in the second quarter compared to $34.59 million in the second quarter of 2017.
In its Q2 2018 earnings conference call, Pfizer (PFE) updated its fiscal 2018 revenue guidance from the previously projected range of $53.5 billion–$55.5 billion to $53.0 billion–$55.0 billion, mainly to account for the unfavorable foreign currency fluctuations from mid-April 2018 to mid-July 2018. Analysts have projected Pfizer’s fiscal 2018 revenues to come in around $54.2 billion, which would be a year-over-year (or YoY) rise of approximately 3.1%. Merck (MRK), Eli Lilly (LLY), and Novartis (NVS) are expected to report revenues close to $42.4 billion, $24.3 billion, and $52.4 billion, respectively, in fiscal 2018.
In the first half of 2018, Novo Nordisk’s fast-acting insulins segment generated revenues of 9.7 billion Danish kroner, reflecting a ~2% YoY (year-over-year) growth in local currencies.
Today, Mylan Pharmaceuticals (MYL) announced the launch of tadalafil tablets USP (20 mg) in the United States. The drug is the first generic version of Eli Lilly’s (LLY) Adcirca (tadalafil) approved by the FDA.
Novo Nordisk’s (NVO) Victoza generated revenues of 11.7 billion Danish kroner in the first half of 2018 compared to 11.5 billion Danish kroner in the first half of 2017, a ~2% YoY (year-over-year) growth and a ~12% YoY growth in local currencies.
Novo Nordisk (NVO) reported net revenues of 54.3 billion Danish kroner in the first half of 2018 compared to 57.1 billion Danish kroner in H1 2017. That’s a ~5% YoY (year-over-year) decline.
Analysts expect Pfizer’s (PFE) adjusted EPS to be $2.99 on revenue of $54.3 billion in 2018, a 3.4% rise compared to $52.5 billion in 2017. Analysts also expect a 10.9% rise in the company’s adjusted net income during 2018, mainly due to a fall in its selling, general, and administrative expenses as well as its lower research and development expenses as a percentage of its sales.
Pfizer’s (PFE) Innovative Health business is focused on developing and commercializing medicines, vaccines, and consumer healthcare products, while its Essential Health business includes legacy brands and generic products, research and development, and its contract manufacturing business.
In Eli Lilly’s (LLY) second-quarter earnings conference call, the company raised its fiscal 2018 non-GAAP EPS guidance from the previously projected range of $5.10–$5.20 to $5.40–$5.50. If we consider the midpoint of the guidance range, the guidance implies a rise of 27% YoY (year-over-year) in the company’s non-GAAP EPS in fiscal 2018. Eli Lilly reduced its fiscal 2018 GAAP EPS guidance from the previously projected range of $4.52–$4.62 to $3.19–$3.29 due to higher charges associated with in-process research and development related to the acquisition of ARMO BioSciences.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Health care stocks have made a sharp break to the upside so far in the third quarter, leading the S&P 500 Index (SPX) and outpacing tech stocks in the process. As measured by both the S&P 500 Health Care Index and the Health Care Select Sector SPDR ETF ( XLV), health care stocks closed Monday just 1.8% below their record highs set in January. "Overall they look quite good," said Matt Maley, equity strategist at Miller Tabak, in an interview with CNBC.
In its second-quarter earnings conference call, Merck (MRK) updated its revenue guidance range from the previous guidance of $41.8 billion–$43 billion to $42 billion–$42.8 billion. The updated guidance includes a favorable impact of mid-July foreign currency rates. The company also narrowed and increased its non-GAAP EPS guidance range from $4.16–$4.28 to $4.22–$4.30 despite an unfavorable impact of 100 basis points projected at mid-July foreign currency rates.
Pfizer (PFE) released its second-quarter earnings results on July 31. Pfizer surpassed Wall Street analysts’ consensus estimates for EPS and revenue. Pfizer’s top line increased 4% to ~$13.47 million in the second quarter, including a 2% rise in operating revenue and a 2% favorable impact of foreign exchange.
The name Valeant Pharmaceuticals might be in the dustbin, but Bausch Health Companies still faces an uphill earnings battle with investors, analysts say.